Topical therapy.

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Standard treatment for distal ulcerative colitis involves topical mesalazine and/or corticosteroids.
• Rectal mesalazine demonstrates higher efficacy compared to rectal corticosteroids, including budesonide.
• Topical therapies are crucial for managing distal ulcerative colitis.

Purpose of the Study:

• To evaluate the efficacy of topical mesalazine and budesonide in treating distal ulcerative colitis.
• To compare the effectiveness of monotherapy versus combination therapy.
• To assess the impact of treatment duration and formulation on therapeutic outcomes.

Main Methods:

• Review of current therapeutic strategies for distal ulcerative colitis.
• Comparison of efficacy data for rectal mesalazine versus rectal corticosteroids (budesonide).
• Analysis of treatment outcomes based on dosage, duration, and formulation (enemas vs. foams).

Main Results:

• Topical mesalazine is the primary treatment of choice for mild to moderate distal ulcerative colitis.
• Doses of 1g or higher of mesalazine are equally effective; 4 weeks of treatment is superior to 2 weeks.
• Rectal budesonide (2mg/day) is indicated for nonresponse or intolerance to mesalazine, with minimal adverse events. Combination therapy with mesalazine and budesonide shows enhanced efficacy.

Conclusions:

• Topical mesalazine is the most effective first-line therapy for distal ulcerative colitis.
• Rectal budesonide serves as a viable alternative for specific patient groups.
• Rectal foam preparations improve adherence and tolerability compared to enemas.